Selected Start-Ups (05/00)
Executive Summary
In Vivo summarizes the technologies of several recently founded companies: Avantium B.V., a joint venture of GSE Systems, Shell International Chemical, SmithKline Beecham, WR Grace & Co. and three Dutch universities, will employ high-speed experimentation and simulation technologies to speed product development in the chemical and pharmaceutical industries. Framingham Genomic Medicine will assemble, analyze and expand data from the Framingham Heart Study and make it available to pharmaceutical companies to aid in their drug discovery and development efforts. Ireland's HiberGen Ltd. will use SNaPIT, its proprietary SNP genotyping platform, to identify "disease genes" and conduct pharmacogenomic analysis in the development of individualized therapeutics and diagnostics. iMEDD Inc. will create therapeutic microdevices for delivering drugs directly to the part of the body where they are needed. Using a genomic based drug discovery platform licensed from Brown University, Nemogen Inc. will create pharmaceuticals for enhancing memory and learning. PointDX Inc. is developing integrated imaging analysis and reporting software which it claims will produce faster, cheaper, more accurate radiology reports than the current dictation or future voice recognition processes allow.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.